RESEARCH ARTICLE 99m Tc-labeled Rituximab for Imaging B Lymphocyte Infiltration in Inflammatory Autoimmune Disease Patients

Purpose: The rationale of the present study was to radiolabel rituximab with 99m-technetium and to image B lymphocytes infiltration in the affected tissues of patients with chronic inflammatory autoimmune diseases, in particular, the candidates to be treated with unlabelled rituximab, in order to provide a rationale for ‘evidence-based’ therapy. Procedures: Rituximab was labelled with 99m Tc via 2-ME reduction method. In vitro quality controls of 99m Tc-rituximab included stability assay, cysteine challenge, SDS-PAGE, immunoreactive fraction assay and competitive binding assay on CD20+ve Burkitt lymphoma-derived cells. For the human pilot study, 350–370 MBq (100 μg) of 99m Tc-rituximab were injected in 20 patients with different chronic inflammatory autoimmune diseases. Whole body anteroposterior planar scintigraphic images were acquired 6 and 20 h p.i. Results: Rituximab was labelled to a high labelling efficiency (998%) and specific activity (3515– 3700 MBq/mg) with retained biochemical integrity, stability and biological activity. Scintigraphy with 99m Tc-rituximab in patients showed a rapid and persistent spleen uptake, and the kidney appeared to be a prominent source for the excretion of radioactivity. Inflamed joints showed a variable degree of uptake at 6 h p.i. in patients with rheumatoid arthritis indicating patient variability; similarly, the salivary and lacrimal glands showed variable uptake in patients with Sjogren’s syndrome, Behcet’s disease and sarcoidosis. Inflammatory disease with particular characteristics showed specific uptake in inflammatory lesions, such as, dermatopolymyositis patients showed moderate to high skin uptake, a sarcoidosis patient showed moderate lung uptake, a Behcet’s disease patient showed high oral mucosa uptake and a polychondritis patient showed moderate uptake in neck cartilages. In one patient with systemic lupus erythematosus, we did not find any non-physiological uptake. Conclusion: Rituximab can be efficiently labelled with 99m Tc with high labelling efficiency. The results suggest that this technique might be used to assess B lymphocyte infiltration in affected organs in patients with autoimmune diseases; this may provide a rationale for anti-CD20 therapies.

[1]  A. Signore,et al.  Targeting T and B lymphocytes with radiolabelled antibodies for diagnostic and therapeutic applications. , 2010, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[2]  G. Piaggio,et al.  Molecular imaging of inflammation/infection: nuclear medicine and optical imaging agents and methods. , 2010, Chemical reviews.

[3]  J. Fransen,et al.  The Disease Activity Score and the EULAR response criteria. , 2009, Rheumatic diseases clinics of North America.

[4]  R. Dierckx,et al.  Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  J. Fettich,et al.  99mTc-labelled rituximab, a new non-Hodgkin's lymphoma imaging agent: first clinical experience , 2008, Nuclear medicine communications.

[6]  R. Fleischmann,et al.  Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. , 2008, Clinical therapeutics.

[7]  T. Huizinga,et al.  Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. , 2007, Arthritis and rheumatism.

[8]  T. Hartman,et al.  Diagnosis of interstitial lung diseases. , 2007, Mayo Clinic proceedings.

[9]  R. Priori,et al.  New radiopharmaceuticals for imaging rheumatoid arthritis. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[10]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[11]  Andreas Radbruch,et al.  B cells in autoimmunity: more than antibodies? , 2005 .

[12]  B. Kotzin The role of B cells in the pathogenesis of rheumatoid arthritis. , 2005, The Journal of rheumatology. Supplement.

[13]  F. Buchegger,et al.  131I-rituximab: relationship between immunoreactivity and specific activity. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  G. Burmester,et al.  The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. , 2003, Current opinion in rheumatology.

[15]  R. Fanin,et al.  Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. , 2002, Arthritis and rheumatism.

[16]  R. Jonsson,et al.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group , 2002, Annals of the rheumatic diseases.

[17]  P. Klimiuk,et al.  T Cell Activation in Rheumatoid Synovium Is B Cell Dependent1 , 2001, The Journal of Immunology.

[18]  S. L. Bridges,et al.  Pathogenesis of rheumatoid arthritis. Role of B lymphocytes. , 2001, Rheumatic diseases clinics of North America.

[19]  L. Wedderburn,et al.  B cells in autoimmunity. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[20]  K. Kurdziel The panda sign. , 2000, Radiology.

[21]  D. Sackett,et al.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. , 1992, Arthritis and rheumatism.

[22]  M. Dalakas Polymyositis, dermatomyositis and inclusion-body myositis. , 1991, The New England journal of medicine.

[23]  F. Arnett Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.

[24]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[25]  A. Freedman,et al.  The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. , 1985, Journal of immunology.

[26]  P. Bunn,et al.  Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. , 1984, Journal of immunological methods.

[27]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[28]  L. Nadler,et al.  Characterization of a human B lymphocyte-specific antigen. , 1980, Journal of immunology.

[29]  C. Pearson,et al.  RELAPSING POLYCHONDRITIS: Prospective Study of 23 Patients and A Review of the Literature , 1976, Medicine.

[30]  C. Berek,et al.  Role of B Cells in the Pathogenesis of Rheumatoid Arthritis , 2012, BioDrugs.